Gilead reported Phase 2 SWIFT results for emvistegrast, an oral a4b7 integrin inhibitor in ulcerative colitis, showing higher clinical response rates at the 200 mg dose versus placebo. In the report, 66% of patients on the highest dose achieved clinical response compared with 37% on placebo, meeting the primary endpoint nominally.